PMID- 33519195
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220420
IS  - 1177-889X (Print)
IS  - 1177-889X (Electronic)
IS  - 1177-889X (Linking)
VI  - 15
DP  - 2021
TI  - Oncologist and Patient Preferences for Novel Agents in First-Line Treatment for 
      Chronic Lymphocytic Leukemia: Commonalities and Disconnects.
PG  - 99-110
LID - 10.2147/PPA.S289139 [doi]
AB  - PURPOSE: Treatment for chronic lymphocytic leukemia (CLL) has changed 
      dramatically with the approval of novel agents. Information regarding how 
      patients and oncologists make trade-offs across attributes of novel therapies is 
      limited. The purpose of this study was to understand how variations in attributes 
      impact treatment choice among patients and oncologists. PATIENTS AND METHODS: In 
      this study, 371 participants (patients [n=220] and oncologists [n=151]) completed 
      an online discrete choice experiment (DCE) to quantify preferences for first-line 
      (1L) CLL treatment with novel agents; participants chose between hypothetical 
      treatment profiles consisting of eight attributes with varying levels taken from 
      published literature. Hierarchical Bayesian models were used to estimate 
      attribute level preference weights. The weights were used to compute relative 
      importance, a measure of how influential an attribute is to treatment choice. 
      RESULTS: Increasing 2-year progression-free survival (PFS) from 75% to 95% had 
      the greatest impact on preferences in 1L CLL treatment, accounting for 40% and 
      30% of the variation in preferences among patients and oncologists, respectively. 
      Risk differences in atrial fibrillation (AF), infection, and discontinuation due 
      to adverse events (AEs) were also important to patients and oncologists. Among 
      both groups, risk differences in tumor lysis syndrome (TLS) and bleeding were 
      least influential in treatment choice. Oncologists required 2-4 times higher 
      increases in 2-year PFS than patients to accept increased risks of AF, 
      discontinuation due to AEs, bleeding, TLS, and arthralgia/myalgia. CONCLUSION: 
      Patient-oncologist communication may be improved by a more focused discussion on 
      the risks of AEs, relative to treatment outcomes, with patient goals in mind.
CI  - (c) 2021 Le et al.
FAU - Le, Hannah
AU  - Le H
AD  - US Medical Affairs, AstraZeneca, Gaithersburg, MD, USA.
FAU - Ryan, Kellie
AU  - Ryan K
AD  - US Medical Affairs, AstraZeneca, Gaithersburg, MD, USA.
FAU - Wahlstrom, Svea K
AU  - Wahlstrom SK
AD  - US Patient Safety, AstraZeneca, Wilmington, DE, USA.
FAU - Maculaitis, Martine C
AU  - Maculaitis MC
AD  - Kantar, Health Division, New York, NY, USA.
FAU - Will, Oliver
AU  - Will O
AD  - Kantar, Health Division, Horsham, PA, USA.
FAU - Mulvihill, Emily
AU  - Mulvihill E
AD  - Kantar, Health Division, St. Louis, MO, USA.
FAU - LeBlanc, Thomas W
AU  - LeBlanc TW
AD  - Division of Hematologic Malignancies and Cellular Therapy, Duke University, 
      Durham, NC, USA.
LA  - eng
PT  - Journal Article
DEP - 20210122
PL  - New Zealand
TA  - Patient Prefer Adherence
JT  - Patient preference and adherence
JID - 101475748
PMC - PMC7837542
OTO - NOTNLM
OT  - B-cell
OT  - chronic
OT  - leukemia
OT  - lymphocytic
OT  - oncologists
OT  - progression-free survival
OT  - tumor lysis syndrome
COIS- HL, KR, and SKW: Employees of AstraZeneca. MCM, EM, and OW: Employees of Kantar, 
      which received funding from AstraZeneca to conduct this study. TWL: Personal fees 
      for consulting or advisory boards: AbbVie, Agios, Amgen, AstraZeneca, 
      BMS/Celgene, CareVive, Daiichi-Sankyo, Otsuka, Pfizer, Seattle Genetics; 
      Royalties: UpToDate; Speakers bureaus/honoraria: AbbVie, Agios, BMS/Celgene; 
      Grants/research contracts: American Cancer Society, AstraZeneca, CareVive, Duke 
      University, Flatiron, Helsinn, Heron, Jazz Pharmaceuticals, NINR/NIH, Seattle 
      Genetics. The authors report no other conflicts of interest in this work.
EDAT- 2021/02/02 06:00
MHDA- 2021/02/02 06:01
PMCR- 2021/01/22
CRDT- 2021/02/01 05:53
PHST- 2020/10/29 00:00 [received]
PHST- 2021/01/07 00:00 [accepted]
PHST- 2021/02/01 05:53 [entrez]
PHST- 2021/02/02 06:00 [pubmed]
PHST- 2021/02/02 06:01 [medline]
PHST- 2021/01/22 00:00 [pmc-release]
AID - 289139 [pii]
AID - 10.2147/PPA.S289139 [doi]
PST - epublish
SO  - Patient Prefer Adherence. 2021 Jan 22;15:99-110. doi: 10.2147/PPA.S289139. 
      eCollection 2021.